Journal Article

Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C Post-liver transplantation increases sustained virologic response: A retrospective review

Marotta, Paul, Roth, Lee, Bain, Vincent, Chandok, Natasha, Aljudaibi, Bandar, Wells, Malcolm, Mason, Andrew, Levstik, Mark

2013

Overview

Background/Aim: In patients with advanced post-transplant hepatitis C virus (HCV) recurrence, antiviral treatment (AVT) with interferon and ribavirin is indicated to prevent graft failure. The aim of this study was to determine and report Canadian data with respect to the safety, efficacy, and spontaneous virologic response (SVR) predictors of AVT among transplanted patients with HCV recurrence. Patients and Methods: A retrospective chart review was performed on patients transplanted in London, Ontario and Edmonton, Alberta from 2002 to 2012 who were treated for HCV. Demographic, medical, and treatment information was collected and analyzed. Results: A total of 85 patients with HCV received pegylated interferon with ribavirin post-liver transplantation and 28 of the 65 patients (43%) with genotype 1 achieved SVR. Of the patients having genotype 1 HCV who achieved SVR, there was a significantly lower stage of fibrosis (1.37 ± 0.88 vs. 1.89 ± 0.96; P = 0.03), increased ribavirin dose (total daily dose 1057 ± 230 vs. 856 ± 399 mg; P = 0.02), increased rapid virologic response (RVR) (6/27 vs. 0/31; P = 0.05), increased early virologic response (EVR) (28/28 vs. 18/35; P = 0.006), and longer duration of therapy (54.7 ± 13.4 weeks vs. 40.2 ± 18.7; P = 0.001). A logistic regression model using gender, age, RVR, EVR, anemia, duration of therapy, viral load, years′ post-transplant, and type of organ (donation after cardiac death vs. donation after brain death) significantly predicted SVR (P < 0.001), with duration of therapy having a significant odds ratio of 1.078 (P = 0.007). Conclusions: This study identified factors that predict SVR in HCV-positive patients who received dual therapy post-transplantation. Extending therapy from 48 weeks to 72 weeks of dual therapy is associated with increased SVR rates. Future studies examining the role of extended therapy are needed to confirm these findings, since the current study is a retrospective one.

• Publisher: Medknow Publications,Medknow Publications and Media Pvt. Ltd,Medknow Publications & Media Pvt. Ltd,Medknow Publications & Media Pvt Ltd,Wolters Kluwer Medknow Publications
• Subject: Adult / Age / Aged / Confidence Intervals / Databases, Factual / Dosage and administration / Dose-Response Relationship, Drug / Drug Administration Schedule / Drug therapy / Drug Therapy, Combination / Female / Follow-Up Studies / Genotype / Genotype & phenotype / Graft Rejection - prevention & control / Graft Survival / Hepacivirus - drug effects / Hepacivirus - genetics / Hepatitis / Hepatitis C / Hepatitis C virus / Hepatitis C, Chronic - diagnosis / Hepatitis C, Chronic - drug therapy / Hepatitis C, Chronic - physiopathology / Humans / Interferon / Interferon-alpha - administration & dosage / Liver / Liver Failure - surgery / Liver Failure - virology / liver transplant / Liver Transplantation - adverse effects / Liver Transplantation - methods / Logistic Models / Male / Middle Aged / Multivariate Analysis / Original / Polyethylene Glycols - administration & dosage / Recombinant Proteins - administration & dosage / Recurrence / Retrospective Studies / retrospective study / Ribavirin / Ribavirin - administration & dosage / Risk factors / RNA, Viral - drug effects / Time Factors / Transplantation / Transplants & implants / Treatment Outcome / Viral Load - drug effects